Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-20-047642

Chief Business Development Off sold 416 shares at $41.57 ($17,293)

  • Chief Business Development Off acquired 416 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-08-19 Option exercise +416 $6.27 $2,608 416 D
BENZENO SHARON Chief Business Development Off 2020-08-19 Sale −416 $41.57 $17,293 0 D
Derivatives
BENZENO SHARON Chief Business Development Off 2020-08-19 Option exercise · Stock Option (Right to Buy) −416 3,334 D
Open-market sales · 416 sh · avg $41.57 · $17,293
Loading xslF345X03/doc4.xml…